Cilta-Talq Fusion Study

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
31 patients (estimated)
Sponsors
Medical College of Wisconsin
Tags
Bispecific Antibody, GPRC5D, Pre-CAR T
Trial Type
Treatment
Last Update
SparkCures ID
2177
NCT Identifier
NCT07093554

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.